
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated strong financial performance, with a 30% year-over-year revenue growth in fourth quarter 2024, contributing to an anticipated $370 million in revenue for 2025. The company also reported a steady 14% increase in testing volume, rising from 39,900 in the previous quarter to 45,500, indicating consistent demand for its precision medicine services. Furthermore, CareDx's financial position remains robust, with cash and investments increasing to $261 million by the end of December 2024, signaling a solid foundation for continued growth and operations.
Bears say
CareDx Inc faces significant financial risks that contribute to a negative outlook on its stock. The company's revenue generation is heavily reliant on testing services, putting it at risk if it fails to secure adequate reimbursement rates or if competitors develop superior technologies, which could lead to market share loss. Additionally, potential regulatory changes, integration challenges from acquisitions, and vulnerabilities in intellectual property protection pose considerable threats that could adversely affect CareDx’s future financial performance, as highlighted by its recent EBITDA guidance falling short of expectations and a reported net loss.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares